ESG Clinical Studies2018-08-24T12:08:49-07:00
Results from Intragastric Balloon Procedure

ESG Clinical Study Results

ESG Weight Loss Advantage

In a clinical study, 91 patients underwent ESG from August 2013 through March 2016. All patients were clinically obese with a body mass index (BMI) greater than 30 kg/m² and had failed non-invasive weight loss measures, or had a BMI greater than 40 kg/m² and were either not considered as surgical candidates or had refused surgery.

Six months after the procedure, patients in the study had lost 14.4% of their total body weight, 17.6% weight loss at 12 months, and 20.9% weight loss at 24 months. In addition to sustained total body weight loss up to 24 months post procedure, ESG reduced key indicators of hypertension and diabetes and hypertriglyceridemia. 

What’s more, patients not only lose weight, but also experience significant improvements in markers of diabetes, high blood pressure, blood cholesterol levels, and sleep apnea.

  • This field is for validation purposes and should be left unchanged.